Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous and Donor-derived CD7 CAR T-cell Therapy in Refractory or Relapsed T-cell Malignancies: a Multi-center, Open-label, Phase Ⅰ/Ⅱ Clinical Trial

NCT06316427 is registered in ClinicalTrials.gov with Beijing GoBroad Hospital as lead sponsor.

NCT NCT06316427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06316427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous and Donor-derived CD7 CAR T-cell Therapy in Refractory or Relapsed T-cell Malignancies: a Multi-center, Open-label, Phase Ⅰ/Ⅱ Clinical Trial
Lead sponsor
Beijing GoBroad Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 22, 2024
Completion date
March 30, 2028
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, in relapse, refractory acute lymphoblastic leukemia, t-cell acute lymphoblastic leukemia, t-cell malignancies